GB0013810D0 - Biological products - Google Patents

Biological products

Info

Publication number
GB0013810D0
GB0013810D0 GBGB0013810.7A GB0013810A GB0013810D0 GB 0013810 D0 GB0013810 D0 GB 0013810D0 GB 0013810 A GB0013810 A GB 0013810A GB 0013810 D0 GB0013810 D0 GB 0013810D0
Authority
GB
United Kingdom
Prior art keywords
biological products
biological
products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0013810.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Original Assignee
Celltech Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0013810(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech Chiroscience Ltd filed Critical Celltech Chiroscience Ltd
Priority to GBGB0013810.7A priority Critical patent/GB0013810D0/en
Publication of GB0013810D0 publication Critical patent/GB0013810D0/en
Priority to PT91762518T priority patent/PT2230308E/pt
Priority to DE10192353T priority patent/DE10192353T1/de
Priority to EP10010795.2A priority patent/EP2308975B1/en
Priority to KR1020027001131A priority patent/KR20020047097A/ko
Priority to IL14799201A priority patent/IL147992A0/xx
Priority to ES10010795.2T priority patent/ES2600080T3/es
Priority to OA1200200368A priority patent/OA12282A/en
Priority to DK01934209.6T priority patent/DK1287140T3/da
Priority to MYPI20012634A priority patent/MY136603A/en
Priority to CA2380298A priority patent/CA2380298C/en
Priority to LTEP10010795.2T priority patent/LT2308975T/lt
Priority to DK09176251.8T priority patent/DK2230308T3/da
Priority to BRPI0106682A priority patent/BRPI0106682B8/pt
Priority to EP01934209A priority patent/EP1287140B1/en
Priority to APAP/P/2002/002690A priority patent/AP2092A/en
Priority to MXPA01013440A priority patent/MXPA01013440A/es
Priority to TR2019/00227T priority patent/TR201900227T4/tr
Priority to PT16154916T priority patent/PT3059314T/pt
Priority to SI200131056A priority patent/SI2308975T1/sl
Priority to ES16154916T priority patent/ES2707714T3/es
Priority to CA2707766A priority patent/CA2707766C/en
Priority to SI200130960T priority patent/SI1287140T1/sl
Priority to PL353960A priority patent/PL212738B1/pl
Priority to AT01934209T priority patent/ATE451460T1/de
Priority to SI200131020T priority patent/SI2230308T1/sl
Priority to DK16154916.7T priority patent/DK3059314T3/en
Priority to SK315-2002A priority patent/SK288343B6/sk
Priority to CNB018016294A priority patent/CN1289671C/zh
Priority to ES09176251T priority patent/ES2403217T3/es
Priority to CZ20020837A priority patent/CZ300737B6/cs
Priority to EP16154916.7A priority patent/EP3059314B1/en
Priority to DE122010000027C priority patent/DE122010000027I1/de
Priority to PT01934209T priority patent/PT1287140E/pt
Priority to HK03103635.2A priority patent/HK1051385B/en
Priority to DK10010795.2T priority patent/DK2308975T3/da
Priority to HUP1600483A priority patent/HU230669B1/hu
Priority to PL399351A priority patent/PL218516B1/pl
Priority to AU60511/01A priority patent/AU783756B2/en
Priority to ES01934209T priority patent/ES2337763T3/es
Priority to NZ516596A priority patent/NZ516596A/en
Priority to ES200250012A priority patent/ES2230975B2/es
Priority to DE60140738T priority patent/DE60140738D1/de
Priority to PT100107952T priority patent/PT2308975T/pt
Priority to BR0106682-0A priority patent/BR0106682A/pt
Priority to GB0128386A priority patent/GB2366800B/en
Priority to JP2002502126A priority patent/JP4064812B2/ja
Priority to HU0202346A priority patent/HU230561B1/hu
Priority to RU2002105922/13A priority patent/RU2303604C2/ru
Priority to EP09176251A priority patent/EP2230308B1/en
Priority to HU1600016A priority patent/HU230553B1/hu
Priority to PCT/GB2001/002477 priority patent/WO2001094585A1/en
Priority to TW090113707A priority patent/TWI316088B/zh
Priority to PE2001000529A priority patent/PE20020292A1/es
Priority to ARP010102689A priority patent/AR033978A1/es
Priority to TW096150671A priority patent/TWI353358B/zh
Priority to US09/875,221 priority patent/US7012135B2/en
Priority to US09/949,559 priority patent/US7186820B2/en
Priority to IS6217A priority patent/IS2808B/is
Priority to ZA200200097A priority patent/ZA200200097B/xx
Priority to BG106278A priority patent/BG66072B1/bg
Priority to IL147992A priority patent/IL147992A/en
Priority to NO20020554A priority patent/NO334808B1/no
Priority to EC2002004210A priority patent/ECSP024210A/es
Priority to US11/374,231 priority patent/US7402662B2/en
Priority to JP2006285205A priority patent/JP4476989B2/ja
Priority to US12/141,667 priority patent/US7977464B2/en
Priority to IL195085A priority patent/IL195085A0/en
Priority to JP2009003953A priority patent/JP5185143B2/ja
Priority to CY20101100219T priority patent/CY1109889T1/el
Priority to FR10C0015C priority patent/FR10C0015I2/fr
Priority to LU91674C priority patent/LU91674I2/fr
Priority to BE2010C019C priority patent/BE2010C019I2/fr
Priority to CY2010011C priority patent/CY2010011I1/el
Priority to HK11102887.9A priority patent/HK1148776B/en
Priority to IS8986A priority patent/IS3016B/is
Priority to CY20131100333T priority patent/CY1114143T1/el
Priority to NO20131316A priority patent/NO339282B1/no
Priority to NO2014026C priority patent/NO2014026I2/no
Priority to NO20160694A priority patent/NO341218B1/no
Priority to CY20161101159T priority patent/CY1118220T1/el
Priority to HUS1700013C priority patent/HUS1700013I1/hu
Priority to CY20191100095T priority patent/CY1121173T1/el
Priority to CY2019018C priority patent/CY2019018I2/el
Priority to NL300982C priority patent/NL300982I9/nl
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
GBGB0013810.7A 2000-06-06 2000-06-06 Biological products Ceased GB0013810D0 (en)

Priority Applications (85)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products
PT91762518T PT2230308E (pt) 2000-06-06 2001-06-05 Moléculas de anticorpo tendo especificidade para o factor de necrose tumoral alfa humano e uso das mesmas
DE10192353T DE10192353T1 (de) 2000-06-06 2001-06-05 Antikörpermolekül mit Spezifität für humanen Tumornekrosefaktor alpha und deren Verwendung
EP10010795.2A EP2308975B1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
KR1020027001131A KR20020047097A (ko) 2000-06-06 2001-06-05 인간 종양괴사인자 알파에 특이성을 갖는 항체 분자 및그의 용도
IL14799201A IL147992A0 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
ES10010795.2T ES2600080T3 (es) 2000-06-06 2001-06-05 Moléculas de anticuerpo que tienen especificidad por el factor de necrosis tumoral alfa humano y sus usos
OA1200200368A OA12282A (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof.
DK01934209.6T DK1287140T3 (da) 2000-06-06 2001-06-05 Antistofmolekyler, der har specificitet overfor human tumornekrosefaktor-alfa og anvendelse deraf
MYPI20012634A MY136603A (en) 2000-06-06 2001-06-05 Biological products
CA2380298A CA2380298C (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
LTEP10010795.2T LT2308975T (lt) 2000-06-06 2001-06-05 Antikūno molekulės, specifiškos žmogaus naviko nekrozės faktoriui alfa, ir jų panaudojimas
DK09176251.8T DK2230308T3 (da) 2000-06-06 2001-06-05 Antistofmolekyle, der har specificitet for human tumornekrosisfaktor-alfa, og anvendelse deraf
BRPI0106682A BRPI0106682B8 (pt) 2000-06-06 2001-06-05 molécula de anticorpo, composto, seqüência de dna, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo e uso do composto
EP01934209A EP1287140B1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
APAP/P/2002/002690A AP2092A (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof.
MXPA01013440A MXPA01013440A (es) 2000-06-06 2001-06-05 Moleculas de anticuerpo que tienen especificidad por el factor de necrosis tumoral alfa humano, y uso de las mismas.
TR2019/00227T TR201900227T4 (tr) 2000-06-06 2001-06-05 İnsan tümör nekroz faktörü alfa için özgünlüğü olan antikor molekülleri ve bunların kullanımı.
PT16154916T PT3059314T (pt) 2000-06-06 2001-06-05 Moléculas de anticorpo possuindo especificidade para fator de necrose de tumor alfa humano, e suas utilizações
SI200131056A SI2308975T1 (sl) 2000-06-06 2001-06-05 Molekule protitelesa, ki imajo specifičnost za človeške tumorje nekrotizirajoči faktor alfa, in uporabe le-teh
ES16154916T ES2707714T3 (es) 2000-06-06 2001-06-05 Moléculas de anticuerpos que tienen especificidad por factores alfa humanos de necrosis tumoral, y uso de las mismas
CA2707766A CA2707766C (en) 2000-06-06 2001-06-05 Plasmids ptqomp and ptto-1 which have an ompa signal sequence
SI200130960T SI1287140T1 (sl) 2000-06-06 2001-06-05 Molekule protiteles, specifižśnih za žśloveĺ ki tumorski nekrozni faktor alfa, in njihova uporaba
PL353960A PL212738B1 (pl) 2000-06-06 2001-06-05 Czasteczka przeciwciala, zwiazek, sekwencja DNA, wektor do klonowania lub ekspresji, komórka gospodarza, sposób wytwarzania czasteczki przeciwciala, kompozycja terapeutyczna lub diagnostyczna, zastosowanie czasteczki przeciwciala albo zwiazku
AT01934209T ATE451460T1 (de) 2000-06-06 2001-06-05 Antikörpermoleküle mit spezifizität für menschlichen tumornekrosefaktor-alpha, und deren verwendung
SI200131020T SI2230308T1 (sl) 2000-06-06 2001-06-05 Molekule protiteles, specifičnih za humani tumorski nekrozni faktor alfa, in njih uporaba
DK16154916.7T DK3059314T3 (en) 2000-06-06 2001-06-05 ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR HUMAN TUMOR CANCER FACTOR ALPHA AND USE THEREOF
SK315-2002A SK288343B6 (sk) 2000-06-06 2001-06-05 Molekuly protilátky, ktoré sú špecifické pre humánny nádorový nekrotický faktor alfa a ich použitie
CNB018016294A CN1289671C (zh) 2000-06-06 2001-06-05 对人肿瘤坏死因子α具有特异性的抗体分子及其用途
ES09176251T ES2403217T3 (es) 2000-06-06 2001-06-05 Moléculas de anticuerpo que tienen especificidad por el factor de necrosis tumoral alfa humano y sus usos
CZ20020837A CZ300737B6 (cs) 2000-06-06 2001-06-05 Molekula protilátky specifická pro humánní TNFalfa, sloucenina obsahující molekulu protilátky, sekvence DNA, klonovací nebo expresní vektor, hostitelská bunka, zpusob prípravy molekuly protilátky, terapeutická nebo diagnostická kompozice a použití mo
EP16154916.7A EP3059314B1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
DE122010000027C DE122010000027I1 (de) 2000-06-06 2001-06-05 Antikörpermoleküle mit spezifizität für menschlichen tumornekrosefaktor-alpha, und deren verwendung
PT01934209T PT1287140E (pt) 2000-06-06 2001-06-05 Moléculas de anticorpo com especificidade para o factor de necrose tumoral humano alfa e sua utilização
HK03103635.2A HK1051385B (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
DK10010795.2T DK2308975T3 (da) 2000-06-06 2001-06-05 Antistofmolekyler, der har specificitet for human tumor nekrotiserende faktor alfa, og anvendelse deraf
HUP1600483A HU230669B1 (hu) 2000-06-06 2001-06-05 Humán tumor nekrózis faktor alfa specifikus antitest molekulák és alkalmazásuk
PL399351A PL218516B1 (pl) 2000-06-06 2001-06-05 Cząsteczka przeciwciała, związek zawierający cząsteczkę przeciwciała, sekwencja DNA, wektor do klonowania lub ekspresji, komórka gospodarza, sposób wytwarzania cząsteczki przeciwciała, kompozycja terapeutyczna lub diagnostyczna, zastosowanie cząsteczki przeciwciała albo związku
AU60511/01A AU783756B2 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
ES01934209T ES2337763T3 (es) 2000-06-06 2001-06-05 Moleculas de anticuerpos que tienen especificidad por el factor alfa de necrosis tumoral humana y uso de las mismas.
NZ516596A NZ516596A (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
ES200250012A ES2230975B2 (es) 2000-06-06 2001-06-05 "moleculas de anticuerpo que tienen especificidad por el factor de necosis tumoral alfa humano y uso de las mismas".
DE60140738T DE60140738D1 (de) 2000-06-06 2001-06-05 Antikörpermoleküle mit spezifizität für menschlichen tumornekrosefaktor-alpha, und deren verwendung
PT100107952T PT2308975T (pt) 2000-06-06 2001-06-05 Moléculas de anticorpos com especificidade para o fator de necrose tumoral alfa humano e suas utilizações
BR0106682-0A BR0106682A (pt) 2000-06-06 2001-06-05 Molécula de anticorpo, variante de molécula de anticorpo, anticorpo, composto, sequência de dna, vetor de clonagem ou de expressão, vetor de expressão de e. coli, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo, vetorpdnabeng-g1, vetorptto(cdp870), e, polipeptìdeo
GB0128386A GB2366800B (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha,and use thereof
JP2002502126A JP4064812B2 (ja) 2000-06-06 2001-06-05 ヒト腫瘍壊死因子αに対する特異性を有する抗体分子およびそれらの使用
HU0202346A HU230561B1 (hu) 2000-06-06 2001-06-05 Humán tumor nekrózis faktor-alfa specifikus antitest molekulák és alkalmazásuk
RU2002105922/13A RU2303604C2 (ru) 2000-06-06 2001-06-05 Молекулы антител, обладающие специфичностью в отношении фактора некроза альфа опухоли человека, и их применение
EP09176251A EP2230308B1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
HU1600016A HU230553B1 (hu) 2000-06-06 2001-06-05 Humán tumor nekrózis faktor alfa specifikus antitest molekulák és alkalmazásuk
PCT/GB2001/002477 WO2001094585A1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
TW090113707A TWI316088B (en) 2000-06-06 2001-06-06 Anti-tnf alpha antibodies and their uses
PE2001000529A PE20020292A1 (es) 2000-06-06 2001-06-06 Anticuerpos que tienen especificidad por el factor de necrosis tumoral
ARP010102689A AR033978A1 (es) 2000-06-06 2001-06-06 Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
TW096150671A TWI353358B (en) 2000-06-06 2001-06-06 Anti-tnfα antibodies and their uses
US09/875,221 US7012135B2 (en) 2000-06-06 2001-06-06 Biological products
US09/949,559 US7186820B2 (en) 2000-06-06 2001-09-10 Production of humanised antibodies to TNFα
IS6217A IS2808B (is) 2000-06-06 2002-01-03 Mótefnasameindir sem eru með sérvirkni fyrir æxlisdrepboða alfa í mönnum og notkun þeirra
ZA200200097A ZA200200097B (en) 2000-06-06 2002-01-04 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof.
BG106278A BG66072B1 (bg) 2000-06-06 2002-01-04 Специфични молекули на антитела за човешки туморен некрозен фактор алфа, и тяхното използване
IL147992A IL147992A (en) 2000-06-06 2002-02-04 Molecules of antibodies specific for human TNF, compounds and compositions containing them, a DNA sequence encoding a heavy and light chain of said antibody and processes for the production of said antibody
NO20020554A NO334808B1 (no) 2000-06-06 2002-02-04 CDR-podet antistoffmolekyl med spesifisitet for human TNF-alfa, forbindelse inneholdende antistoffmolekylet, DNA, klonings- eller ekspresjonsvektor, E.coli ekspresjonsvektor, vertscelle, fremgangsmåte for fremstilling av antistoffmolekylet, terapeutisk eller diagnostisk preparat, samt anvendelse av antistoffmolekylet
EC2002004210A ECSP024210A (es) 2000-06-06 2002-02-06 Moléculas de anticuerpo que tienen especificidad por el factor de necrosis tumoral alfa humano, y uso de las mismas
US11/374,231 US7402662B2 (en) 2000-06-06 2006-03-13 Antibody molecules specific to human tumor necrosis factor alpha
JP2006285205A JP4476989B2 (ja) 2000-06-06 2006-10-19 ヒト腫瘍壊死因子αに対する特異性を有する抗体分子およびそれらの使用
US12/141,667 US7977464B2 (en) 2000-06-06 2008-06-18 Antibody molecules specific to human tumour necrosis factor alpha
IL195085A IL195085A0 (en) 2000-06-06 2008-11-03 Antibody molecules having specifity for human tnf ?? compounds and composition comprising them, dna sequence encoding heavy and light chain of said antibody and process for the production of said antibody
JP2009003953A JP5185143B2 (ja) 2000-06-06 2009-01-09 ヒト腫瘍壊死因子αに対する特異性を有する抗体分子およびそれらの使用
CY20101100219T CY1109889T1 (el) 2000-06-06 2010-03-09 Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων
FR10C0015C FR10C0015I2 (fr) 2000-06-06 2010-03-15 Molecules d'anticorps a specificite pour le facteur alpha de necrose tumorale humaine, et leurs utilisations
LU91674C LU91674I2 (fr) 2000-06-06 2010-03-29 Cimzia-certolizumab pegol
BE2010C019C BE2010C019I2 (enExample) 2000-06-06 2010-04-13
CY2010011C CY2010011I1 (el) 2000-06-06 2010-05-13 Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων
HK11102887.9A HK1148776B (en) 2000-06-06 2011-03-22 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
IS8986A IS3016B (is) 2000-06-06 2011-11-18 Mótefnasameindir sem eru með sérvirkni fyrir æxlisdrepsþátt alfa í mönnum og notkun þeirra
CY20131100333T CY1114143T1 (el) 2000-06-06 2013-04-23 Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
NO20131316A NO339282B1 (no) 2000-06-06 2013-10-01 Antistoff-molekyler med spesifisitet for human tumornekrosefaktor-alfa, og anvendelse derav
NO2014026C NO2014026I2 (no) 2000-06-06 2014-10-23 Certolizumab pegol
NO20160694A NO341218B1 (no) 2000-06-06 2016-04-26 Antistoffmolekyl med spesifisitet for human tumornekrosefaktor-alfa, DNA, klonings- og ekspresjonsvektor, vertscelle, fremgangsmåte for fremstilling av antistoffmolekylet samt terapeutisk preparat
CY20161101159T CY1118220T1 (el) 2000-06-06 2016-11-10 Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
HUS1700013C HUS1700013I1 (hu) 2000-06-06 2017-04-06 Humán tumor nekrózis faktor-alfa specifikus antitest molekulák és alkalmazásuk
CY20191100095T CY1121173T1 (el) 2000-06-06 2019-01-24 Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
CY2019018C CY2019018I2 (el) 2000-06-06 2019-04-19 Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
NL300982C NL300982I9 (nl) 2000-06-06 2019-04-24 Certolizumab

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products

Publications (1)

Publication Number Publication Date
GB0013810D0 true GB0013810D0 (en) 2000-07-26

Family

ID=9893121

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0013810.7A Ceased GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products
GB0128386A Expired - Lifetime GB2366800B (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha,and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB0128386A Expired - Lifetime GB2366800B (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha,and use thereof

Country Status (42)

Country Link
US (4) US7012135B2 (enExample)
EP (4) EP1287140B1 (enExample)
JP (3) JP4064812B2 (enExample)
KR (1) KR20020047097A (enExample)
CN (1) CN1289671C (enExample)
AP (1) AP2092A (enExample)
AR (1) AR033978A1 (enExample)
AT (1) ATE451460T1 (enExample)
AU (1) AU783756B2 (enExample)
BE (1) BE2010C019I2 (enExample)
BG (1) BG66072B1 (enExample)
BR (2) BR0106682A (enExample)
CA (2) CA2707766C (enExample)
CY (6) CY1109889T1 (enExample)
CZ (1) CZ300737B6 (enExample)
DE (3) DE10192353T1 (enExample)
DK (4) DK2308975T3 (enExample)
EC (1) ECSP024210A (enExample)
ES (5) ES2600080T3 (enExample)
FR (1) FR10C0015I2 (enExample)
GB (2) GB0013810D0 (enExample)
HU (4) HU230553B1 (enExample)
IL (3) IL147992A0 (enExample)
IS (2) IS2808B (enExample)
LT (1) LT2308975T (enExample)
LU (1) LU91674I2 (enExample)
MX (1) MXPA01013440A (enExample)
MY (1) MY136603A (enExample)
NL (1) NL300982I9 (enExample)
NO (4) NO334808B1 (enExample)
NZ (1) NZ516596A (enExample)
OA (1) OA12282A (enExample)
PE (1) PE20020292A1 (enExample)
PL (2) PL218516B1 (enExample)
PT (4) PT2308975T (enExample)
RU (1) RU2303604C2 (enExample)
SI (3) SI2230308T1 (enExample)
SK (1) SK288343B6 (enExample)
TR (1) TR201900227T4 (enExample)
TW (2) TWI353358B (enExample)
WO (1) WO2001094585A1 (enExample)
ZA (1) ZA200200097B (enExample)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
ES2358505T3 (es) * 2002-03-20 2011-05-11 Ucb Pharma, S.A. Métodos para analizar isómeros de disulfuro de anticuerpos.
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
JP4418745B2 (ja) * 2002-05-28 2010-02-24 ユセベ ファルマ ソシエテ アノニム 抗体ｐｅｇ位置異性体、それを含む組成物及びその使用
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040131614A1 (en) * 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
US20040091490A1 (en) * 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
US20040247588A1 (en) * 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP2311867A1 (en) 2002-10-29 2011-04-20 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
WO2004065417A2 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2004074345A2 (en) * 2003-02-19 2004-09-02 Pharmacia Corporation Carbonate esters of polyethylene glycol activated by means of oxalate esters
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
JP5087274B2 (ja) * 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
SI1656455T1 (sl) * 2003-08-13 2012-12-31 Sandoz Ag Postopek za čiščenje rekombinantnih polipeptidov
JP5544063B2 (ja) * 2003-08-13 2014-07-09 サンド・アクチエンゲゼルシヤフト 組換えポリペプチドの生産のための発現ベクター、形質転換宿主細胞及び発酵方法
GB0319601D0 (en) 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
WO2006062776A2 (en) * 2004-11-29 2006-06-15 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
JP5757495B2 (ja) * 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
CN101189265B (zh) * 2005-06-01 2012-07-04 米克罗麦特股份公司 抗il2抗体
EP1891110A2 (en) 2005-06-07 2008-02-27 Esbatech AG STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
GB0520169D0 (en) 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
EP2004231A4 (en) 2006-04-07 2013-07-10 Nektar Therapeutics CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
JP5385135B2 (ja) 2006-07-03 2014-01-08 チャールズ デイビッド アデア， 細胞接着分子の発現を調節するための組成物
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2678367C (en) * 2007-03-02 2014-07-08 Farnam Companies, Inc. Sustained release compositions using wax-like materials
WO2008153997A1 (en) * 2007-06-07 2008-12-18 Brookwood Pharmaceuticals, Inc. Reduced-mass, long-acting dosage forms
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
EP2185188B1 (en) * 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
BRPI0907485A2 (pt) * 2008-02-05 2015-08-04 Delenex Therapeutics Ag Polipeptídeos de ligação a antígeno contra degeneração de cartilagem
ES2549903T3 (es) * 2008-05-07 2015-11-03 Argos Therapeutics, Inc. Anticuerpos humanizados contra interferón alfa humano
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
EP3964526A1 (en) 2008-06-25 2022-03-09 Novartis AG Humanization of rabbit antibodies using a universal antibody framework
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
NZ593905A (en) * 2009-01-29 2013-03-28 Abbott Lab Il-1 binding proteins
ES2804450T3 (es) 2009-07-10 2021-02-08 Ablynx Nv Método para la producción de dominios variables
CA2774692C (en) 2009-09-24 2017-12-19 Ucb Pharma S.A. Bacterial strain for recombinant protein expression, having protease deficient degp retaining chaperone activity, and knocked out tsp and ptr genes
MY173390A (en) 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
EP2542258A4 (en) 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES
BR112012022338A2 (pt) 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais direcionados a cd20
MX2012011629A (es) 2010-04-07 2013-03-05 Abbvie Inc Proteinas de union a tnf-alfa.
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP2714912B1 (en) 2011-06-01 2018-05-02 Intrexon Actobiotics NV Polycistronic expression system for bacteria
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
SMT201800068T1 (it) 2011-07-13 2018-03-08 Ucb Biopharma Sprl Ceppo ospite batterico che esprime dsbc ricombinante
CN103917639B (zh) 2011-09-23 2017-09-26 英特瑞克斯顿阿克图比奥帝克斯有限公司 经修饰的革兰氏阳性细菌及其用途
HUE038830T2 (hu) 2011-09-23 2018-11-28 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
WO2013087914A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
RU2666990C2 (ru) 2012-08-13 2018-09-13 Дженентек, Инк. Антитела к jagged и способы их применения
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
ES3046837T3 (en) 2014-12-22 2025-12-02 UCB Biopharma SRL Method of protein manufacture
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
JP7292877B2 (ja) 2016-01-14 2023-06-19 イントレクソン・アクトバイオテイクス・エヌブイ １型糖尿病を処置するための組成物および方法
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
RS62040B1 (sr) 2016-06-02 2021-07-30 Abbvie Inc Agonist receptora glukokortikoida i njegovi imunokonjugati
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
EP3658192B1 (en) 2017-12-01 2021-04-28 AbbVie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
KR102323342B1 (ko) 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
WO2022172085A2 (en) 2021-02-15 2022-08-18 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
JP2024531480A (ja) 2021-08-26 2024-08-29 デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド ステロイド化合物及びそのコンジュゲート
US20250368732A1 (en) 2021-09-24 2025-12-04 Xbrane Biopharma Ab Dna constructs and host cells for expressing recombinant protein
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
IL328082A (en) 2023-11-06 2026-06-01 Momenta Pharmaceuticals Inc Compositions and methods for treating rheumatoid arthritis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
CA2163032C (en) * 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
WO1996033204A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
IL195085A0 (en) 2009-08-03
ATE451460T1 (de) 2009-12-15
CY2010011I2 (el) 2012-01-25
EP3059314A1 (en) 2016-08-24
LT2308975T (lt) 2016-11-10
BR0106682A (pt) 2002-05-14
FR10C0015I2 (fr) 2011-12-30
EP2308975B1 (en) 2016-08-10
AP2002002690A0 (en) 2002-12-31
ES2230975A1 (es) 2005-05-01
NO2014026I1 (no) 2014-10-23
EP2230308A1 (en) 2010-09-22
US7012135B2 (en) 2006-03-14
GB2366800A (en) 2002-03-20
AR033978A1 (es) 2004-01-21
US7186820B2 (en) 2007-03-06
SI1287140T1 (sl) 2010-04-30
HUP1600483A2 (enExample) 2002-10-28
CY2010011I1 (el) 2012-01-25
SK288343B6 (sk) 2016-04-01
DK2308975T3 (da) 2016-10-31
CY1109889T1 (el) 2012-01-25
BRPI0106682B8 (pt) 2021-05-25
AP2092A (en) 2010-02-28
HUP0202346A2 (en) 2002-10-28
CY2019018I1 (el) 2020-05-29
IS2808B (is) 2012-09-15
ES2600080T3 (es) 2017-02-07
HK1148776A1 (en) 2011-09-16
JP5185143B2 (ja) 2013-04-17
CN1289671C (zh) 2006-12-13
NO20131316L (no) 2002-04-08
BRPI0106682B1 (pt) 2020-10-13
HUP0202346A3 (en) 2004-11-29
LU91674I9 (enExample) 2019-01-03
CN1383450A (zh) 2002-12-04
FR10C0015I1 (enExample) 2010-04-16
CY1121173T1 (el) 2020-05-29
DK2230308T3 (da) 2013-05-06
GB2366800B (en) 2005-01-19
ECSP024210A (es) 2002-05-23
IS6217A (is) 2002-01-03
PL353960A1 (en) 2003-12-15
CA2380298C (en) 2010-09-28
HUS1700013I1 (hu) 2017-08-28
IL147992A0 (en) 2002-09-12
ES2403217T3 (es) 2013-05-16
JP2003535591A (ja) 2003-12-02
IL147992A (en) 2009-06-15
BG106278A (bg) 2002-12-29
CA2380298A1 (en) 2001-12-13
SI2308975T1 (sl) 2016-11-30
PT2230308E (pt) 2013-05-03
HK1051385A1 (en) 2003-08-01
ES2337763T3 (es) 2010-04-29
EP2230308B1 (en) 2013-01-23
NO20020554D0 (no) 2002-02-04
TW200817430A (en) 2008-04-16
AU6051101A (en) 2001-12-17
TR201900227T4 (tr) 2019-02-21
PT1287140E (pt) 2010-03-08
LU91674I2 (fr) 2010-05-31
US20020151682A1 (en) 2002-10-17
NO2014026I2 (no) 2018-02-14
DK3059314T3 (en) 2019-02-18
EP1287140B1 (en) 2009-12-09
PL212738B1 (pl) 2012-11-30
KR20020047097A (ko) 2002-06-21
HUP1600016A2 (en) 2002-10-28
NO20020554L (no) 2002-04-08
PE20020292A1 (es) 2002-05-08
US20030026805A1 (en) 2003-02-06
JP4476989B2 (ja) 2010-06-09
PT3059314T (pt) 2019-02-01
DK1287140T3 (da) 2010-04-19
NO341218B1 (no) 2017-09-11
BG66072B1 (bg) 2011-01-31
ES2230975B2 (es) 2007-04-16
DE10192353T1 (de) 2003-05-22
NL300982I1 (enExample) 2019-05-01
AU783756B2 (en) 2005-12-01
MXPA01013440A (es) 2003-09-04
SI2230308T1 (sl) 2013-06-28
US7402662B2 (en) 2008-07-22
NO20160694A1 (no) 2002-04-08
CZ300737B6 (cs) 2009-07-29
US20060233800A1 (en) 2006-10-19
IS3016B (is) 2019-10-15
NZ516596A (en) 2004-07-30
CY2019018I2 (el) 2020-05-29
CY1114143T1 (el) 2016-07-27
PL399351A1 (pl) 2012-12-17
RU2303604C2 (ru) 2007-07-27
HU230669B1 (hu) 2017-07-28
WO2001094585A1 (en) 2001-12-13
OA12282A (en) 2006-05-11
EP2308975A1 (en) 2011-04-13
NO339282B1 (no) 2016-11-21
SK3152002A3 (en) 2002-07-02
JP2007105043A (ja) 2007-04-26
HU230553B1 (hu) 2016-11-28
DE122010000027I1 (de) 2010-08-12
EP3059314B1 (en) 2018-10-24
JP2009171966A (ja) 2009-08-06
MY136603A (en) 2008-10-31
CZ2002837A3 (cs) 2002-05-15
EP1287140A1 (en) 2003-03-05
DE60140738D1 (de) 2010-01-21
NL300982I9 (nl) 2019-05-06
CA2707766C (en) 2013-05-21
CY1118220T1 (el) 2017-06-28
GB0128386D0 (en) 2002-01-16
BE2010C019I2 (enExample) 2020-08-20
US20080269465A1 (en) 2008-10-30
TWI316088B (en) 2009-10-21
ES2707714T3 (es) 2019-04-04
US7977464B2 (en) 2011-07-12
NO334808B1 (no) 2014-06-02
PT2308975T (pt) 2016-11-14
ZA200200097B (en) 2003-01-06
TWI353358B (en) 2011-12-01
CA2707766A1 (en) 2001-12-13
HU230561B1 (hu) 2016-12-28
PL218516B1 (pl) 2014-12-31
JP4064812B2 (ja) 2008-03-19

Similar Documents

Publication Publication Date Title
GB0025307D0 (en) Biological products
HUP0401618A3 (en) Biological products
GB0029407D0 (en) Product
DE60137111D1 (en) Biosensor
DE60140000D1 (en) Biosensor
DE60115288D1 (en) Biosensor
DE60119133D1 (en) Biosensor
GB0008368D0 (en) Combination product
DE60121404D1 (en) Biosensor
GB0225279D0 (en) Biological products
GB0224082D0 (en) Biological products
GB0028192D0 (en) Cleaning products
GB0024689D0 (en) Deodorant products
AU144947S (en) Bread product
AU144948S (en) Bread product
GB9919338D0 (en) Biological products
GB9925854D0 (en) Biological products
GB9908816D0 (en) Biological product
GB9925853D0 (en) Biological products
GB9918670D0 (en) Biological product
HUP0100017A3 (en) Bread products
GB0016551D0 (en) Biological products
GB0011193D0 (en) Biological products
GB0108620D0 (en) Biological products
GB9908818D0 (en) Biological product

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)